EBITDA Margin % is calculated as EBITDA divided by its Revenue. Adimmune's EBITDA for the
three
months ended in Dec. 2025 was NT$267 Mil. Adimmune's Revenue for the
three
months ended in Dec. 2025 was NT$745 Mil. Therefore, Adimmune's EBITDA margin for the quarter that ended in Dec. 2025 was 35.88%.
Adimmune (TPE:4142) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Adimmune EBITDA Margin % Related Terms
Adimmune EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Adimmune's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4142 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Adimmune's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adimmune EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adimmune's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Adimmune's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adimmune (TPE:4142) has a EBITDA Margin % of 35.88% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #336 out of 944 companies in the Biotechnology industry, placing it in the top 35.6%.
Is Adimmune's EBITDA Margin % too high?
Adimmune's current EBITDA Margin % is 35.88%. Based on the distribution chart, Adimmune ranks #336 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #336 out of 944 companies for EBITDA Margin %. This puts Adimmune in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adimmune and its competitors. Adimmune's current EBITDA Margin % is 35.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.40, compared to a current price of NT$16.80 — trading 33.9% below its estimated fair value. The current EBITDA Margin % is 35.88%. Adimmune's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Adimmune (TPE:4142), the current EBITDA Margin % is 35.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adimmune (TPE:4142) Overvalued in 2026?
Based on GuruFocus' analysis, Adimmune stock appears to be undervalued.
The current stock price of NT$16.80 is trading 33.9% below its estimated GF Value™ of NT$25.40.
GuruFocus considers Adimmune to be Possible Value Trap.
Key valuation signals for TPE:4142:
EBITDA Margin %: 35.88%
GF Value™: NT$25.40 vs. price of NT$16.80 (33.9% below fair value)
No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score
Get the complete analysis for TPE:4142
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4142 has been successfully added to your 
